Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 403 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Table of Contents
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded111    
    Comments [Add]    

Recommend this journal

Year : 2004  |  Volume : 46  |  Issue : 2  |  Page : 150-155

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia and Schizoaffective Disorders

1 Medical Dept, Solus, A Div. of Ranbaxy, Ranbaxy House, Plot No. 89, Street 15, MIDC, Andheri (W), Mumbai - 400 093, India
2 Biostatistician, Lokmanya Tilak Medical College, Mumbai, India

Correspondence Address:
R K Chavda
Medical Dept, Solus, A Div. of Ranbaxy, Ranbaxy House, Plot No. 89, Street 15, MIDC, Andheri (W), Mumbai - 400 093
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 21408042

Rights and PermissionsRights and Permissions

Before the 1990s, treatment of psychoses centred on conventional agents whose tolerability was limited by extrapyramidal symptoms (EPS). The past decade has seen the emergence of newer generation of antipsychotic agents. These agents provide better negative symptom efficacy, less impaired cognition and lower risk of extrapyramidal syndromes. Aripiprazole, a new atypical antipsychotic drug, displayed efficacy similar to risperidone and haloperidol in numerous clinical trials. Aripiprazole does not cause significant prolactin elevation and is associated with a low rate of clinically significant weight gain compared with other atypical antipsychotics. Aripiprazole is a study drug for treating schizophrenia and has a novel pharmacologic profile. Aripiprazole provides a new treatment option with limited adverse effects for patients in need of antipsychotic therapy. The present study is a 4-week, open-labelled, randomized postmarketing clinical study conducted using aripiprazole as the study drug. Fixed doses of 15mg of the drug were administered throughout the study. A total of 249 patients with a primary diagnosis of schizophrenia or schizoaffective disorder were randomized. Efficacy measures included the Positive And Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative and general psychopathology. Patients were evaluated for efficacy parameters at the end of 2nd week and also at the end of study. Unlike the other antipsychotics, aripiprazole was not associated with significant EPS, increase in body weight or increase in QTc interval. Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder.



Print this article         Email this article